Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

PTAB Institutes Samsung Bioepis IPR Against Regeneron’s Eylea® (aflibercept) Patent

Oct 20, 2023

The US Patent Trial and Appeal Board (PTAB) has instituted Samsung Bioepis’ inter partes review (IPR) against Regeneron’s Eylea® (aflibercept) patent no. 10,888,601 in IPR proceeding IPR2023-00739.  The ‘601 patent relates to methods of use of aflibercept in treating age related macular degeneration, diabetic macular oedema, diabetic retinopathy and angiogenic eye disorders.

On 18 August 2023 Samsung Bioepis filed an IPR petition against Regeneron’s Eylea® patent no. 10,464,992 and sought joinder with the Celltrion IPR filed against the same Regeneron patent on 17 January 2023.